Serum Trimethylamine N-oxide, Carnitine, Choline, and Betaine in Relation to Colorectal Cancer Risk in the Alpha Tocopherol, Beta Carotene Cancer Prevention Study
Open Access
- 31 May 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 26 (6) , 945-952
Abstract
Background: Trimethylamine N-oxide (TMAO), a choline-derived metabolite produced by gut microbiota, and its biomarker precursors have not been adequately evaluated in relation to colorectal cancer risk. Methods: We investigated the relationship between serum concentrations of TMAO and its biomarker precursors (choline, carnitine, and betaine) and incident colorectal cancer risk in a nested case–control study of male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. We measured biomarker concentrations in baseline fasting serum samples from 644 incident colorectal cancer cases and 644 controls using LC/MS-MS. Logistic regression models estimated the ORs and 95% confidence interval (CI) for colorectal cancer by quartile (Q) of serum TMAO, choline, carnitine, and betaine concentrations. Results: Men with higher serum choline at ATBC baseline had approximately 3-fold greater risk of developing colorectal cancer over the ensuing (median ± IQR) 14 ± 10 years (in fully adjusted models, Q4 vs. Q1, OR, 3.22; 95% CI, 2.24–4.61; Ptrend < 0.0001). The prognostic value of serum choline for prediction of incident colorectal cancer was similarly robust for proximal, distal, and rectal colon cancers (all P < 0.0001). The association between serum TMAO, carnitine, or betaine and colorectal cancer risk was not statistically significant (P = 0.25, 0.71, and 0.61, respectively). Conclusions: Higher serum choline concentration (but not TMAO, carnitine, or betaine) was associated with increased risk of colorectal cancer. Impact: Serum choline levels showed strong prognostic value for prediction of incident colorectal cancer risk across all anatomical subsites, suggesting a role of altered choline metabolism in colorectal cancer pathogenesis. Cancer Epidemiol Biomarkers Prev; 26(6); 945–52. ©2017 AACR.Keywords
All Related Versions
Funding Information
- NIH (HHSN261201500005C, R01HL103866, R01DK106000 and 1R01HL126827)
This publication has 39 references indexed in Scilit:
- Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosisNature Medicine, 2013
- Meat-Related Compounds and Colorectal Cancer Risk by Anatomical SubsiteNutrition and Cancer, 2013
- Choline metabolism in malignant transformationNature Reviews Cancer, 2011
- Gut flora metabolism of phosphatidylcholine promotes cardiovascular diseaseNature, 2011
- Red and Processed Meat Consumption and Risk of Incident Coronary Heart Disease, Stroke, and Diabetes MellitusCirculation, 2010
- Choline and betaine in health and diseaseJournal of Inherited Metabolic Disease, 2010
- A Large Prospective Study of Meat Consumption and Colorectal Cancer Risk: An Investigation of Potential Mechanisms Underlying this AssociationCancer Research, 2010
- A Prospective Study of Red and Processed Meat Intake in Relation to Cancer RiskPLOS Medicine, 2007
- Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancersBiochemical and Biophysical Research Communications, 2002
- The Finnish Cancer Registry as Follow-Up Source of a Large Trial CohortActa Oncologica, 2002